ConductScience.org, home

Comparison · NCT03075891-deaths

Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules vs Ivermectin 1% Cream + Oral Placebo Capsules: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules vs Ivermectin 1% Cream + Oral Placebo Capsules: deaths from any cause. Trial comparisons, record NCT03075891-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03075891-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0277wilson
Risk in group 200.000000000000000001730.0271wilson
Risk difference, group 1 minus group 20-0.02710.0277newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules
Ivermectin 1% cream: Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks~Doxycycline 40 mg MR (30 mg Immediate Release \& 10 mg Delayed Release beads) capsules: 1 Capsule once-daily for 12 weeks
0135EG000
Group 2Ivermectin 1% Cream + Oral Placebo Capsules
Ivermectin 1% cream: Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks~Oral placebo capsules: 1 Capsule once-daily for 12 weeks
0138EG001

Harm

What it counts
Total, all-cause mortality
Time frame
From the signing of the informed consent form (ICF) up to week 12

Source ClinicalTrials.gov

Trial

Title
Oracea Soolantra Association in Participants With Severe Rosacea
NCT number
NCT03075891
Phases
PHASE4
Conditions
Rosacea
Interventions
Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules, Oral placebo capsules
Lead sponsor
Galderma R&D
Results first posted
2019-11-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03075891-deaths